Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc’s (the “Company” or “Nanoform“) Board of Directors held its constitutive meeting on April 21, 2026.
The meeting elected the following persons to the Audit and Compensation Committee of the Board of Directors of the Company: Miguel Calado (chairperson) and Jeanne Thoma (ordinary member). Both members have been members of the audit and compensation committee for prior terms, and both are independent from the company and major shareholders. The Audit and Compensation Committee is a permanent committee of the Board of Directors and acts in accordance with its charter as adopted by the Board of Directors.
For further information, please contact:
Peter Hänninen
General Counsel and Chief Development Officer
peter.hanninen@nanoform.com
+358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.